ArticleiScience2026
Engineering T3 and T7 host range to target protein receptors and guide bacterial evolution.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phage engineering holds significant potential for overcoming the challenges that limit phage therapy. A promising yet underutilized approach is engineering phage host range to target specific receptors and guiding bacterial evolution into a desirable trajectory, referred to as evolutionary steering. This requires balancing binding interactions between native and desired receptors, though it is unclear how balancing binding interactions affects host range and resulting evolutionary trajectories. To provide insights, we surveyed a suite of phage engineering methods to program protein-protein interactions between phage and bacteria and then measured host range expansion and evolutionary trajectories. We engineered T3 and T7, both LPS-targeting phages, to target a proteinaceous nanobody receptor. In addition, we discovered that the capsid plays a role in phage host range and can be a potential target for host range expansion. Together, these studies increase the therapeutic potential for T3 and T7, and more broadly for LPS-targeting phages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.